RRIDs were included in the Cancer Immunology Research paper "Conditional PD-1/PD-L1 Probody Therapeutics Induce…" (https://t.co/i9vlXnnRum). We appreciate the author's support of reproducibility. #accelerateopenscience #methodsmatter

#ImmuneCheckpointBlockade can lead to severe #irAEs, which can limit therapeutic efficacy. Authors demonstrate here that #Probody therapeutics effectively localize therapy to sites of tumor growth, thereby reducing toxicities and maintaining efficacy. http

Conditional PD-1/PD-L1 Probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti-PD 1/PD-L1 agents https://t.co/N3Fgli885f

Following three recent papers, new preclinical data on CytomX's Probody® to PD-L1, pacmilimab (CX-072), published in @CIR_AACR– the 1st paper describing conditionally activated PD-1/PD-L1 checkpoint inhibitor effects on systemic immunity & T-cell funct

Conditional PD-1/PD-L1 Probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti-PD 1/PD-L1 agents https://t.co/h0r4X58PGc https://t.co/ezX1zJEt5N